My work focuses on the prevention and treatment of HIV infection.
I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.
I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.
I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.